EXHIBIT 99.1

WaferGen Bio-systems Reports Results for Fourth Quarter and Fiscal Year 2014

Record Growth in 2014 Revenues, up 360 Percent over 2013

Significant Progress Achieved with Single Cell Analysis Technology, Full Commercial Launch Expected by End of 2015

Company Provides 2015 Revenue Guidance of $8.0 - $8.5 Million, Which Would Represent an Increase of 33% - 42%

FREMONT, California -- March 16, 2015
/PRNewswire/ – WaferGen Bio-systems, Inc. (NasdaqCM: WGBS) announced today its financial results for the fourth quarter and year ended December 31, 2014.

Key 2014 and Recent Highlights

·
Full-year 2014 revenue above $6.0 million, in-line with WaferGen’s previously provided guidance, and a 360% increase over 2013
·
Full-year product revenue increased $4.7 million, or 550%, over 2013
·
Established, in concert with partner, BGI, successful proof-of-concept of WaferGen’s single cell technology, which is based on WaferGen’s proprietary SmartChip platform
·
Produced positive results in collaboration with the Broad Institute in a study aimed at validating the utility of WaferGen’s SmartChip technology for isolating and studying single cells via Next-Gen Sequencing (NGS)
·
Entered into a research collaboration with the Familial Breast Cancer Research Unit of the Women’s College Research Institute at the University of Toronto with the goal of enabling affordable, large-scale BRCA1 and BRCA2 screening for the general population
·
Raised $20 million of gross proceeds, providing WaferGen with the resources to grow the Company’s existing business of genetic analysis and library prep products, and further invest in WaferGen’s single cell analysis-focused initiatives
·
Acquired NGS library preparation business from IntegenX Inc., immediately positioning WaferGen as a significant player in the NGS sample prep market
·
Announced that Admera Health will implement WaferGen’s target enrichment technology for NGS as Admera launches PGxOne™ Plus, an expanded version of their proprietary pharmacogenomics test, PGxOne™

“As our revenue growth in 2014 indicates, our business is beginning to gain significant momentum,” said Ivan Trifunovich, President and CEO of WaferGen.  “We have an expanding and diverse customer base, and our focus on the rapidly growing segment of Next-Gen Sequencing continues to enhance our market penetration.  In addition, our SmartChip platform has the potential to play a critical role in the important area of single cell analysis, which has become increasingly important for scientists attempting to unlock the underlying mechanisms of complex diseases, such as diabetes and cancer.  WaferGen intends to launch an Early Access Program for our single cell analysis technology in the second quarter of 2015, and a full commercial launch before the end of 2015.”

Fourth Quarter Financial Results

Total revenue for the fourth quarter of 2014 was $1.6 million, up 229% from $0.5 million in the fourth quarter of 2013.  The increase is primarily due to an increase in SmartChip revenue of $0.6 million, plus Apollo revenue of $0.5 million compared to none in 2013.

 
 

The following information was filed by Wafergen Biosystems, Inc. (WGBS) on Monday, March 16, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Wafergen Biosystems, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Wafergen Biosystems, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account